The Clinical and Regulatory Milestone of Zongertinib in First-Line NSCLC

Hernexeos announced that the U.S. FDA granted Accelerated Approval for the treatment of first-line patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations with Hernexeos.

A Paradigm Shift in Targeted Lung Cancer Care

The approval of zongertinib for patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) who test positive for the EML4-ALK fusion mutation marks a significant expansion of the approved indications for this treatment. Zongertinib was first approved in August 2025 for patients with NSCLC whose disease had progressed on prior cancer therapies. For these patients who test positive for the EML4-ALK fusion mutation, the front-line treatment road ahead now looks significantly better as they can initiate treatment with a targeted approach as opposed to the less than optimal chemo-immunotherapy that was the standard of care for treatment-naïve NSCLC patients.

Zongertinib, an oral, once-daily tyrosine kinase inhibitor, now is indicated for patients with treatment-naive locally advanced or metastatic non-small cell lung cancer with specific epidermal growth factor receptor (EGFR) mutations. This makes zongertinib the first and only TKI indicated for patients with these EGFR mutations. It received FDA review through both the Real-Time Oncology Review (RTOR) pilot and the Commissioner’s National Priority Review Voucher (CNPV) program. 44 days passed from Roche/Genentech submission of the supplemental new drug application.

Why It Matters

Precision Medicine Meets National Priority

Lung cancer is the second most common cancer diagnosis in the U.S. and the leading cause of cancer death in the country. Most (85%) of lung cancers are non-small cell lung cancer (NSCLC) and of these, the most common type is adenocarcinoma. Adenocarcinomas of the lung are classified into subtypes and can be identified by specific biomarkers found within the tumor. Many of these biomarkers can be detected through tumor testing and are targets for therapy. The most common mutated oncogene identified in the study was KRAS, which accounted for 25% of cases, followed by EGFR (17%) and ALK (7%).

1. The Biology of HER2-Mutant NSCLC

HER2 (Human Epidermal Growth Factor Receptor 2) gene mutations are found in 2% to 4% of NSCLC cases, however, given the frequency of lung cancer, this represents thousands of cases every year. These mutations are distinct from HER2 amplification or overexpression found in breast and gastric carcinomas. Lung cancers with HER2 mutations are mostly drivers due to one or a few seminal genetic events that activate the kinase domain. The most common mutations are exon 20 insertions.

The therapeutic paradigm for treatment of HER2 positive non-small cell lung cancer (HER2 NSCLC) has shifted from a chemotherapy-based approach to a more targeted strategy that includes HER2 inhibitors, immune therapies and various combinations of these.

- Antibody-Drug Conjugates (ADCs): Currently viewed as the most effective targeted treatment. - Trastuzumab-deruxtecan (T-DXd): Received accelerated FDA approval in 2022 for second-line HER2-mutant NSCLC based on the DESTINY-Lung trials, which showed an objective response rate (ORR) of approximately 54–55%. - Trastuzumab-emtansine (T-DM1): An alternative ADC, though it has shown more limited efficacy in some trials compared to T-DXd. - Tyrosine Kinase Inhibitors (TKIs): 1. Zongertinib (BI 1810631): A next-generation, selective HER2 TKI that spares EGFR to limit toxicity. 2. Poziotinib: An irreversible TKI that showed moderate efficacy but has been limited by high rates of treatment-related adverse effects. 3. Pyrotinib: An irreversible pan-HER inhibitor approved for breast cancer that has shown activity in HER2-mutant NSCLC, both as monotherapy and in combination with other agents.

Exploring the potential of combination therapies, namely the association of ADCs and TKIs or their combination with ICIs to achieve synergy, is of great interest. Moreover, the search for novel treatments to address unmet medical needs, including brain metastases that affect up to 29% of patients with HER2-altered NSCLC, continues to be an important area of investigation.

While concerns with pulmonary toxicity exist, personalized medicine/molecular profiling has changed the approach and prognosis for this aggressive and lethal cancer. Until the selective TKIs, patients with NSCLC with EML4-ALK fusion were destined for a poor prognosis. Current standard of care treatments achieve an objective response rate (ORR) of 30-45%. Zongertinib has now been approved and is on the market for patients with NSCLC with the EML4-ALK fusion, which is particularly potent in treatment naïve patients with an impressive ORR of 76%, thereby doubling the standard of care.

2. The Innovation of Selectivity: Sparing Wild-Type EGFR

Prior HER2 inhibitors were “on-target, off-tissue” and also inhibited EGFR, leading to unmanageable toxicity for most patients, severe Grade 3 diarrhea and exfoliative skin toxicity. Even a small amount of EGFR inhibition was sufficient to warrant discontinuation of the drug.

Zongertinib is an irreversible, HER2 selective tyrosine kinase inhibitor (TKI) that selectively targets mutated forms of HER2 while sparing wild-type EGFR. It has potent tumour shrinkage activity and improved safety compared with prior TKIs.

3. The Regulatory “National Priority”

The accelerated approval of Zongertinib for the treatment of certain patients with NSCLC marks the second time the FDA has utilized the Commissioner’s National Priority Review Voucher (CNPV) pilot program to expedite the review of a drug to treat a serious or life-threatening disease. The Commissioner’s National Priority Review Voucher was designed to afford the FDA the ability to grant expedited approval of a drug or biological that addresses a national public health priority. The expedited approval of Zongertinib, an oral, targeted, small molecule treatment for patients with particular, rare and aggressive forms of NSCLC, is a top administrative priority for precision oncology.

Who It Affects

The Patient Experience: Oral vs. Infusion

We call this a win for patients with unresectable or metastatic non-small cell lung cancer (NSCLC) with HER2 mutations as they will experience an improvement in quality of life. The only other HER2-targeted option exists in the form of an ADC that is given intravenously over 60 minutes every 3 weeks. Patients and payers will appreciate the convenience and improved efficacy of an oral once daily zongertinib. No longer will patients and their caregivers suffer through “toxic” and time consuming trips to the clinic.

Oncologists and the Testing Mandate

The approval of zongertinib will be significant for the medical community, in that it will enable clinicians to adopt a “test-to-treat” approach. As oncologists, we need to be aware of which patients might be eligible for treatment with zongertinib, and use methods such as comprehensive genomic profiling (CGP) or Next-Generation Sequencing (NGS) at the time of initial diagnosis to identify them (2-4% of patients with NSCLC).

The imperative for speed is unprecedented. By the time NGS results are available, it is too late for chemotherapy benefit and too late to use potentially more effective targeted therapy first. As a result, there is enormous pressure on pathology departments to shorten their TAT. Integrating molecular tumor boards into current clinical workflow practice – already practiced in many academic programs – becomes imperative also in community-based oncology programs.

Payers and the Evidence Burden

We note that achieving a 76% trial response rate is “remarkable” according to the words of the FDA in the press release. While achieving accelerated approval allows for earlier market entry, such approval is still subject to the requirement for confirmation of overall survival (OS) on the indication for which accelerated approval was granted, which in this case is still maturing. Payers (private insurance and Medicare) will be watching the progress of the Phase 3 Beamion LUNG-2 trial where zongertinib is being directly compared to the current standard of care for patients with NSCLC (chemo + immunotherapy). Until results from this trial are reported, biomarker confirmation for coverage is likely.

What Changes

This is an informational leaflet for patients and elaborates on the results from the clinical study Beamion LUNG-1. The main objective of Beamion LUNG-1 was to investigate the effectiveness and safety of Beamion in reducing symptoms of a cough

Beamion LUNG-1 trial data were the basis for approval of Beamion for treatment of NSCLC. In the trial, which included 72 patients with previously untreated systemic disease, there was

• Objective Response Rate (ORR): 76% (with 11% achieving a Complete Response).
• Disease Control Rate (DCR): A staggering 96%, meaning nearly every patient saw some level of tumor stabilization or shrinkage.
• Duration of Response (DOR): 64% of patients maintained their response for at least 6 months, and 44% reached the 12-month mark.
• Intracranial Activity: Crucially, zongertinib showed activity against brain metastases, a common and devastating complication in HER2-mutant NSCLC. In expansion cohorts, the intracranial ORR was 41%, with a DCR of 83% in the brain.

Managing Toxicity

Zongertinib is not side effect free, although it is selective. In the pooled safety population of 292 patients (ECL, China and Asia Pacific ex-Japan and Coop, Europe and other Global), the most common adverse reactions were; diarrhea (45%), decreased weight (30%), nausea (24%), decreased appetite (22%), fatigue (20%), vomiting (14%), decreased albumin (14%), stomatitis (12%), cough (10%), dry mouth (10%) and alopecia (8%).

• Diarrhea (54%) and Rash (27%) remain the most common adverse events, though they are mostly Grade 1 or 2 (mild to moderate).
• Hepatotoxicity (26%): Clinicians must monitor liver enzymes (ALT/AST) regularly, particularly during the first few cycles of treatment.
• Serious Warnings: The label includes warnings for interstitial lung disease (ILD)/pneumonitis, left ventricular dysfunction (cardiac monitoring is required), and embryo-fetal toxicity.

Weight-Based Dosing

Zongertinib should be administered on the basis of patient weight.

• Weight < 90 kg (198 lbs): 120 mg once daily.
• Weight ≥ 90 kg (198 lbs): 180 mg once daily.

The Broader Strategic Landscape

Boehringer Ingelheim has received approval to market zongertinib for the treatment of patients with locally advanced or metastatic, unresectable NSCLC with HER2 mutation. The approval pits the German-based company against a number of other big-pharma giants also targeting the HER2 pathway, including Bayer, which is currently with the USLHA seeking approval of its HER2 inhibitor Hyrnuo for first-line treatment of patients with NSCLC. Boehringer Ingelheim’s zongertinib will be administered once daily, potentially offering the company an edge over Bayer’s twice-daily regimen.

Late-stage clinical trials for patients with metastatic HER2-mutant NSCLC have been expanding. Investigators are now also conducting earlier-stage trials for patients with early-stage HER2-mutant NSCLC. One such trial is the Beamion LUNG-3 study, which is enrolling patients to evaluate zongertinib as an adjuvant treatment (administered after surgery) to prevent recurrence in patients with early-stage HER2-mutant NSCLC; success in this study could potentially integrate zongertinib into curative intent treatment of HER2-mutant NSCLC.

Summary of Practical Takeaways for Clinicians

1. Immediate Testing: NGS should be ordered for all non-squamous NSCLC patients at the time of biopsy.
2. First-Line Preference: With a 76% ORR, zongertinib should be considered the preferred first-line option over chemotherapy for patients with documented HER2 TKD mutations.
3. Brain Metastases: Zongertinib is a viable option for patients with stable or active brain metastases, potentially delaying the need for cranial radiation.
4. Proactive Side-Effect Management: While EGFR-sparing, clinicians should still have diarrhea and rash protocols (e.g., loperamide and topical steroids) ready at the start of therapy.
5. Monitoring: Regular liver function tests and periodic echocardiograms (to check Left Ventricular Ejection Fraction) are mandatory.

A New Benchmark for Precision

Regorafenib received approval from the FDA for the indication of treatment of patients with metastatic gastrointestinal stromal tumor(s) (GIST) who havecarriedged prior treatment with at least three previous lines of therapy in June 2013. Approval was received in June 2026 for zongertinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer with a fastidious HER2 mutation. The FDA’s ability to move at the speed of science when the clinical benefit is clear for patients with HER2-mutant lung cancer is now a reality. The immediate challenge will be to ensure equitable access to the NGS testing that will help find these patients, and the many others for whom similar advances in diagnostics will translate into clinical benefit.

Final results of the confirmatory Beamion LUNG-2 trial are mature for assessment. The critical question for the oncology community is whether or not an initial reduction in tumor size translates into long-term overall survival and possibly redefines NSCLC as a chronic rather than a fatal disease.